Partnership Opportunities Arvinas is a clinical stage biotech with a PROTAC platform and a pipeline focused on oncology and neurology, including vepdegestrant, ARV 393, and ARV 102. The company has signaled openness to external partnerships to advance assets requiring broader development resources, as evidenced by licensing activity with major partners for VEPPANU. This creates strong sales opportunities for licensing or co development deals for late stage or portfolio assets, with options for regional rights. Propose tailored partnership options aligned with Arvinas selective development strategy.

PROTAC Platform Value Arvinas relies on its PROTAC Discovery Engine to degrade disease causing proteins, a differentiator that can accelerate collaborations by offering target discovery, optimization, and protein degradation capabilities. For business development teams there is an opportunity to propose collaboration programs to reduce risk in discovery for potential partner targets or to license PROTAC technology to complement existing oncology or neurology pipelines.

Selective Pipeline Focus Arvinas follows a selective development strategy prioritizing neurological and oncology programs, which means partnerships can be crafted around high probability assets and clear value inflection points. This focus supports co development or exclusive licensing deals on assets with strong data and a clear path to pivotal trials.

External Collaboration Model Based in New Haven at a biotech hub, Arvinas has access to local talent, academic collaboration opportunities, and regional contract research organizations. This setup is favorable for joint development programs and manufacturing partnerships, and business developers can explore regional co development arrangements and licensing deals that may include manufacturing or supply components.

Market Demand Signals Recent investor activity around the first PROTAC approval, plus ongoing pipeline emphasis, signals market interest in externally developed assets. This suggests opportunities to present global licensing and strategic collaborations that unlock development and commercialization potential for the company.